<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803231</url>
  </required_header>
  <id_info>
    <org_study_id>12401</org_study_id>
    <secondary_id>F1K-FR-B009</secondary_id>
    <nct_id>NCT00803231</nct_id>
  </id_info>
  <brief_title>Follow-up Data of Patients Treated With XIGRIS® in France</brief_title>
  <official_title>Follow-up Data of Patients Treated With XIGRIS® DROTRECOGIN ALFA (ACTIVATED) in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The transparency commission wishes that the laboratory Lilly France sets up a follow-up study&#xD;
      describing the conditions of use of Xigris® in France.&#xD;
&#xD;
      The purpose of this study is to describe the characteristics of the treated patients, the&#xD;
      conditions of drug use, in particular the conditions of treatment initiation and the clinical&#xD;
      development of the patients during normal clinical practice, in particular rate and cause of&#xD;
      mortality within one month.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study as defined by the specific requirements of Transparency&#xD;
      Commission are as follows:&#xD;
&#xD;
        -  To describe the characteristics of the patients treated with Xigris®&#xD;
&#xD;
             -  socio-demographic characteristics,&#xD;
&#xD;
             -  clinical profile&#xD;
&#xD;
        -  To determine the conditions of use of Xigris®&#xD;
&#xD;
             -  To describe previous treatments,&#xD;
&#xD;
             -  To observe delay before Xigris® initiation,&#xD;
&#xD;
             -  To describe dose, duration of treatment,&#xD;
&#xD;
             -  To study the concomitant treatments and the associated treatments&#xD;
&#xD;
        -  To describe the clinical evolution of the patients&#xD;
&#xD;
             -  To observe mortality after 1 month&#xD;
&#xD;
             -  To describe reasons of death&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 and 31 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe bleeding events</measure>
    <time_frame>28 and 31 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>28 and 31 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1004</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Retrospective cohort</arm_group_label>
    <description>Patient treated with Xigris between January 2006 and November 2008.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective cohort</arm_group_label>
    <description>Patient treated with Xigris between November 2008 and November 2009.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients treated with Xigris® between January 1st, 2006 and August 31st 2008 in&#xD;
        intensive care units in France will be enrolled retrospectively, whereas all adult patients&#xD;
        treated with Xigris® between September 1st, 2008 and September 1st, 2009 will be enrolled&#xD;
        prospectively.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients are eligible to be included in the study if they meet the following criteria&#xD;
&#xD;
          -  Patients treated with Xigris® during the study period in intensive care units in&#xD;
             France&#xD;
&#xD;
          -  Patients with a minimum age of 18 years&#xD;
&#xD;
          -  Patients who are presenting in the normal course of care&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon- fri 9AM-5PM eastern time (UTC/GMT- 5 hours,EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this study, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>February 1, 2010</last_update_submitted>
  <last_update_submitted_qc>February 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

